• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early renal arterial stent thrombosis associated with the JAK2 V617F mutation.

作者信息

Tabaczewski Piotr, Nadesan Suhasini, Lim Seah H

出版信息

Leuk Res. 2009 Apr;33(4):573-4. doi: 10.1016/j.leukres.2008.06.016. Epub 2008 Jul 18.

DOI:10.1016/j.leukres.2008.06.016
PMID:18639337
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2695997/
Abstract
摘要

相似文献

1
Early renal arterial stent thrombosis associated with the JAK2 V617F mutation.与JAK2 V617F突变相关的早期肾动脉支架血栓形成。
Leuk Res. 2009 Apr;33(4):573-4. doi: 10.1016/j.leukres.2008.06.016. Epub 2008 Jul 18.
2
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].[JAK2V617F突变在慢性骨髓增殖性肿瘤患者中的意义]
Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.
3
The JAK2 V617F mutation and thrombosis.JAK2 V617F突变与血栓形成。
Br J Haematol. 2008 Nov;143(3):307-20. doi: 10.1111/j.1365-2141.2008.07258.x.
4
Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.JAK2基因V617F突变在慢性骨髓增殖性疾病患者中的临床意义
Hematology. 2009 Dec;14(6):323-30. doi: 10.1179/102453309X12473408860226.
5
JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.JAK2（V617F）突变与白塞综合征的血栓形成无关。
Clin Appl Thromb Hemost. 2012 Jul;18(4):421-6. doi: 10.1177/1076029611427440. Epub 2011 Dec 26.
6
Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.韩国骨髓增殖性肿瘤患者的血管事件及其与JAK2突变的关系。
Thromb Haemost. 2009 Mar;101(3):547-51.
7
Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.血管重建性高血压与 JAK2 V617F 阳性骨髓增殖性肿瘤相关，采用血管成形术治疗：2 例病例并文献复习。
J Clin Hypertens (Greenwich). 2018 Apr;20(4):798-804. doi: 10.1111/jch.13257. Epub 2018 Apr 14.
8
Splenomegaly and the JAK2 V617F mutation.脾肿大与JAK2 V617F突变
Eur J Intern Med. 2017 Jan;37:e45-e46. doi: 10.1016/j.ejim.2016.09.026. Epub 2016 Oct 7.
9
JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.232例慢性骨髓增殖性肿瘤患者的JAK2 V617F突变状态
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):525-33. doi: 10.1016/j.clml.2014.02.013. Epub 2014 Mar 5.
10
JAK2V617F mutation in patients with thrombosis: to screen or not to screen?血栓形成患者的 JAK2V617F 突变：筛查还是不筛查？
Int J Lab Hematol. 2011 Apr;33(2):117-24. doi: 10.1111/j.1751-553X.2010.01275.x. Epub 2010 Dec 1.

引用本文的文献

1
Possible interesting link between Janus kinase 2 mutation and renovascular hypertension.Janus激酶2突变与肾血管性高血压之间可能存在的有趣联系。
J Clin Hypertens (Greenwich). 2018 Apr;20(4):805-806. doi: 10.1111/jch.13274. Epub 2018 Apr 14.
2
Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.血管重建性高血压与 JAK2 V617F 阳性骨髓增殖性肿瘤相关，采用血管成形术治疗：2 例病例并文献复习。
J Clin Hypertens (Greenwich). 2018 Apr;20(4):798-804. doi: 10.1111/jch.13257. Epub 2018 Apr 14.

本文引用的文献

1
Malignancy: an unrecognized risk factor for coronary stent thrombosis?恶性肿瘤：冠状动脉支架血栓形成的一个未被认识的危险因素？
J Invasive Cardiol. 2008 Apr;20(4):E120-3.
2
Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation.冠状动脉支架植入术后促血栓形成和促炎物质释放的时间进程。
Thromb Haemost. 2008 Apr;99(4):739-48. doi: 10.1160/TH07-05-0365.
3
Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis.
J Am Coll Cardiol. 2007 Nov 20;50(21):2095-7. doi: 10.1016/j.jacc.2007.08.015. Epub 2007 Nov 5.
4
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.药物洗脱支架和裸金属支架相关的结局：一项协作网络荟萃分析。
Lancet. 2007 Sep 15;370(9591):937-48. doi: 10.1016/S0140-6736(07)61444-5.
5
JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.无明显骨髓增殖性疾病情况下非内脏静脉血栓形成中JAK2V617F的患病率和等位基因负荷。
Leukemia. 2007 Aug;21(8):1828-9. doi: 10.1038/sj.leu.2404710. Epub 2007 Apr 26.
6
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.内脏或脑静脉血栓形成且无明显慢性骨髓增殖性疾病患者中JAK2 V617F突变的发生率。
J Thromb Haemost. 2007 Apr;5(4):708-14. doi: 10.1111/j.1538-7836.2007.02424.x. Epub 2007 Jan 29.
7
Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project.与药物洗脱冠状动脉支架相关的超敏反应病例：药物不良事件及报告研究（RADAR）项目现有病例综述
J Am Coll Cardiol. 2006 Jan 3;47(1):175-81. doi: 10.1016/j.jacc.2005.07.071. Epub 2005 Dec 1.
8
Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.血管内超声引导下无抗凝治疗的冠状动脉支架置入时代的亚急性支架血栓形成：发生率、预测因素及临床结局
J Am Coll Cardiol. 1997 Jan;29(1):6-12. doi: 10.1016/s0735-1097(96)00452-4.